(Q35617324)

9 August 2017

1 reference

title

Viral hepatitis C. (English)

1 reference

9 August 2017

1 reference

Thierry Poynard

1

0 references

author name string

Man-Fung Yuen

series ordinal

2

1 reference

9 August 2017

Vlad Ratziu

series ordinal

3

1 reference

9 August 2017

Ching Lung Lai

series ordinal

4

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

362

1 reference

9 August 2017

issue

9401

1 reference

9 August 2017

page(s)

2095-2100

1 reference

Hepatitis C virus infection

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

1 reference

7 January 2021

Hepatocellular carcinoma: an epidemiologic view

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Modeling the hepatitis C virus epidemic in France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Comparing the public health burden of chronic hepatitis C and HIV infection in France

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Fibrosis in patients with chronic hepatitis C: detection and significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Histological features predictive of liver fibrosis in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Sex and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Contribution of obesity to hepatitis C-related fibrosis progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Hepatitis C: A Multifaceted Disease: Review of Extrahepatic Manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Extrahepatic manifestations of hepatitis C among United States male veterans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Psychiatric disorders among veterans with hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Cytokines and chemokines in the immune response to hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Appropriateness of liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Interferon therapy prolonged life expectancy among chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2915109-4

7 January 2021

10.1016/S0140-6736(03)15109-4

Identifiers

DOI

1 reference

9 August 2017

1 reference